National Technical Reports Library

The National Technical Information Service acquires, indexes, abstracts, and archives the largest collection of U.S. government-sponsored technical reports in existence. The NTRL offers online, free and open access to these authenticated government technical reports. Technical reports and documents in its repository may be available online for free either from the issuing federal agency, the U.S. Government Publishing Office’s Federal Digital System website, or through search engines.

Details

Phase I Clinical Testing Antimalarial Drugs.

ADA058221

Publication Date	1978
Personal Author	Reba, R. C.
Page Count	46
Abstract	The safety and tolerance of mefloquine 500 mg weekly over 52 weeks was determined in a study involving 50 subjects. A comprehensive study of the pharmacokinetics of mefloquine was also undertaken. Mefloquine methanesulfonate was shown to be unsafe when administered parenterally because of local tissue irritation. A concomitant decrease in serum haptoglobin was noted with infusion of this drug which is at present unexplained. A pharmacokinetics study of WR 184,806.H3PO4 (involving 20 subjects) was completed. A study to evaluate the gastrointestinal absorption kinetics of WR 30090 (oleic acid) was started but suspended pending the resolution of difficulties with the drug assay. A study to compare the bioavailability of the Walter Reed and Hoffmann-LaRoche formulations of mefloquine hydrochloride has just been completed. (Author)
Keywords	Antimalarials Pharmacology Safety Tolerances(Physiology) Biochemistry Test methods Malaria Drugs Military medicine Mefloquine Experimental data Physiological effects
Source Agency	Non Paid ADAS
NTIS Subject Category	57Q - Pharmacology & Pharmacological Chemistry
Corporate Authors	Bio-Med Inc Washington DC
Document Type	Technical Report
Title Note	Rept. no. 3 (Annual) Feb 77-Jan 78.
NTIS Issue Number	197824
Contract Number	DAMD17-75-C-5036

Phase I Clinical Testing Antimalarial Drugs.

Phase I Clinical Testing Antimalarial Drugs.
ADA058221

Publication Date	1978
Personal Author	Reba, R. C.
Page Count	46
Abstract	The safety and tolerance of mefloquine 500 mg weekly over 52 weeks was determined in a study involving 50 subjects. A comprehensive study of the pharmacokinetics of mefloquine was also undertaken. Mefloquine methanesulfonate was shown to be unsafe when administered parenterally because of local tissue irritation. A concomitant decrease in serum haptoglobin was noted with infusion of this drug which is at present unexplained. A pharmacokinetics study of WR 184,806.H3PO4 (involving 20 subjects) was completed. A study to evaluate the gastrointestinal absorption kinetics of WR 30090 (oleic acid) was started but suspended pending the resolution of difficulties with the drug assay. A study to compare the bioavailability of the Walter Reed and Hoffmann-LaRoche formulations of mefloquine hydrochloride has just been completed. (Author)
Keywords	Antimalarials Pharmacology Safety Tolerances(Physiology) Biochemistry Test methods Malaria Drugs Military medicine Mefloquine Experimental data Physiological effects
Source Agency	Non Paid ADAS
NTIS Subject Category	57Q - Pharmacology & Pharmacological Chemistry
Corporate Authors	Bio-Med Inc Washington DC
Document Type	Technical Report
Title Note	Rept. no. 3 (Annual) Feb 77-Jan 78.
NTIS Issue Number	197824
Contract Number	DAMD17-75-C-5036